Arialys
La Jolla, United States · Founded 2022 · $72.8M raised
- Headquarters
- La Jolla
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- arialysrx.com
- Total Funding
- $72.8M
- Last Round
- $14.8M Venture RoundJun 2025
- Rounds
- 2
About
Arialys Therapeutics is a clinical-stage biotechnology company based in La Jolla, California, developing precision medicines that target autoimmune neuropsychiatric diseases, including anti-NMDA receptor encephalitis. The company was founded by Avalon Bioventures, Catalys Pacific, and MPM to explore recent discoveries in autoimmune neuropsychiatry, with a focus on blocking disease-causing pathogenic antibodies. Its lead candidate, ART5803, holds FDA Rare Pediatric Disease designation.
Summary
Arialys is a Biotech company based in La Jolla, United States, founded in 2022. It has raised $72.8M in total across 2 rounds, most recently a $14.8M Venture Round round in Jun 2025. Investors include Avalon BioVentures, Alexandria Venture Investments and Catalys Pacific.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...